1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in neurofibromatosis (NF) research. Studies supported by this award mechanism should lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.Distinctive Features:• Innovation: The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, examine existing problems from novel perspectives, or exhibit other highly creative qualities.• Preliminary Data: Preliminary and/or published data is encouraged but not required.
Funding Opportunity Number: HT942526NFRPEHDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $1.3M total program funding.
Get alerted about grants like this
Get emailed when new opportunities from “Defense Health Agency Contracting Activity - DHACA” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $1.3M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for DoW Neurofibromatosis Exploration-Hypothesis Development Award are due September 22, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — DoW Neurofibromatosis Exploration-Hypothesis Development Award is offered by Defense Health Agency Contracting Activity - DHACA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Concept Award supports highly innovative, untested, potentially groundbreaking concepts, theories, paradigms and/or basic kidney cancer research. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation in kidney cancer. Applications must describe how the new concept will be innovative and present a novel course of investigation in the field of kidney cancer. Distinctive Features: • Preliminary data are not allowed. • This is a blinded funding mechanism. Applications to this funding opportunity will undergo a double-blinded peer review. Applications must not include any materials that may identify the Principal Investigator (PI), a collaborator, or the organization of the PI or collaborator. • Due to the blinded nature of the review process, identifying or making references to the PI, collaborator(s), or their organization(s) in the proposal (Project Narrative, List of Abbreviations, Acronyms, Symbols, Statement of Work, Impact Statement and Innovation Statement) is prohibited and will result in administrative rejection of the application. Funding Opportunity Number: HT942526KCRPCA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $840K total program funding.
DoW Peer Reviewed Medical, Research Advancement Award is sponsored by Defense Health Agency Contracting Activity - DHACA. Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Research Advancement Award supports fundamental research studies that will make an important contribution towards research, patient care, and/or quality of life for a disease or condition related…
Elevance Health Foundation's maternal/infant health RFP closes July 31, 2026, part of a five-year, $150 million commitment. Last cycle it awarded 29 grants totaling $6.5M across the pregnancy continuum. Here is what the funder actually rewards — measurable disparity reduction, a 15% indirect-cost cap, and scalable models — plus how nonprofits in the 10 priority states should frame a competitive proposal.
Read articleThe Elevance Health Foundation's Maternal/Infant Health RFP funds nonprofits — up to ~$1M over 1-3 years — working to close disparities across the full pregnancy journey. Applications close July 31, 2026, with a national track and a local track in ten named states. Here's how the funder thinks, what 'measurable outcomes' really means here, and how to build a proposal that clears the bar.
Read articleARPA-H's 2026 SBIR/STTR BAA opens seven transformative health topics with $600K Phase I and $3.5M Phase II contracts — non-dilutive, milestone-driven money. The July 10 Solution Summary gate decides who ever gets to pitch. Here's how the ARPA-H model differs from NIH and how small health-tech firms actually get through the funnel.
Read article